DCGI issues notices to Tata 1mg, Amazon and 18 Other epharmacies for rule violations

Share via:

The DCGI has issued show-cause notices to 20 epharmacies, including Tata 1mg, Amazon, and Flipkart, for selling and distributing drugs in violation of the Drugs and Cosmetics Act, 1940.

The companies have been asked to explain why they should not face consequences for breaking the rules. The Drugs and Cosmetics Act of 1940 governs drug importation, manufacturing, and distribution in India. The DCGI stated in the notice that the sale, stock, exhibit, or offer for sale or distribution of drugs through online, internet, or other electronic platforms without a licence may have an impact on drug quality and pose a risk to public health due to potential drug misuse through self-medication and indiscriminate use of the drugs.

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Popular

More Like this

DCGI issues notices to Tata 1mg, Amazon and 18 Other epharmacies for rule violations

The DCGI has issued show-cause notices to 20 epharmacies, including Tata 1mg, Amazon, and Flipkart, for selling and distributing drugs in violation of the Drugs and Cosmetics Act, 1940.

The companies have been asked to explain why they should not face consequences for breaking the rules. The Drugs and Cosmetics Act of 1940 governs drug importation, manufacturing, and distribution in India. The DCGI stated in the notice that the sale, stock, exhibit, or offer for sale or distribution of drugs through online, internet, or other electronic platforms without a licence may have an impact on drug quality and pose a risk to public health due to potential drug misuse through self-medication and indiscriminate use of the drugs.

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

More like this

You can now use the Microsoft Copilot bot on...

Copilot is a chatbot based on OpenAI’s GPT-4...

China’s $47B semiconductor fund puts chip sovereignty front and...

China has closed a third state-backed investment fund...

AI models have favorite numbers, because they think they’re...

AI models are always surprising us, not just...

Popular

Upcoming Events

Startup Information that matters. Get in your inbox Daily!